Specific miRNAs in peripheral plasma for pre-eclampsia and application thereof

A preeclampsia-specific technique applied in the field of molecular biology

Pending Publication Date: 2021-02-23
THE SECOND HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although its exact mechanism of action remains to be elucidated, miRNAs have promising clinical applications as candidate molecules for identifying PE.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Specific miRNAs in peripheral plasma for pre-eclampsia and application thereof
  • Specific miRNAs in peripheral plasma for pre-eclampsia and application thereof
  • Specific miRNAs in peripheral plasma for pre-eclampsia and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Preeclampsia patients (PE, n=22) and non-preeclampsia pregnant women (Control, CTR, n=40) who delivered in the obstetrics department of our hospital during 2019-2020 were selected. Termination of pregnancy by uterine delivery.

[0022] 1. Sample preparation: Anticoagulate 5ml of peripheral blood with EDTA, centrifuge at 1000g for 5min at 4°C, collect plasma and store it in a low-temperature refrigerator for later use;

[0023] 2. RNA extraction: take 300μl plasma, centrifuge at 4°C, 1000g for 5min; take 250μl upper plasma, add TRI successively and chloroform, centrifuge to take 400 μl of the supernatant, add isopropanol and glycogen, discard the supernatant after centrifugation; add 75% ethanol to wash the precipitate and dry it, and finally add 25 μl of RNase-free water preheated to 65°C to dissolve the RNA.

[0024] 3. cDNA synthesis: mix equal amounts of reverse transcription primers into 2μM mixed reverse transcription primers; thaw the reverse transcription kit o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides specific miRNAs in peripheral plasma for pre-eclampsia and application thereof. The nucleotide sequence of the miRNAs is shown as SEQ ID NO. 1. According to the invention, the specific miRNAs in the peripheral plasma for pre-eclampsia can be stably expressed in the peripheral plasma of pre-eclampsia patients and the peripheral plasma of pregnant women with the same gestational weeks but without pre-eclampsia, and there is an obvious difference in the expression of the specific miRNAs between the pre-eclampsia patients and the pregnant women with the same gestational weeks but without pre-eclampsia. The specific miRNAs can be applied to early identification of the pre-eclampsia, and can be served as quantitative indexes for timely termination of pregnancy of the pre-eclampsia patients.

Description

technical field [0001] The invention belongs to the field of molecular biology, and in particular relates to a specific miRNAs in peripheral plasma of preeclampsia and its application. Background technique [0002] Preeclampsia (Pre-eclampsia, PE) is a disease unique to women during pregnancy, with an incidence rate of 0.2-2%, and is closely related to spontaneous abortion, fetal intrauterine growth restriction, placental abruption and premature delivery. The disease is insidious, can progress rapidly and continue to deteriorate, and is prone to serious complications such as acute renal failure, liver failure, cerebral hemorrhage, disseminated intravascular coagulation, and even endangers the lives of mothers and fetuses, seriously endangering the health of mothers and babies. At present, the effective treatment measures for pregnant women with preeclampsia are based on the termination of pregnancy after weighing the advantages and disadvantages of the mother and fetus, whic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883C12N15/113
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 顾艳华绍芳王建梅范卓然辛亚维盛红娜鞠宝辉
Owner THE SECOND HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products